GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Epizyme Inc (NAS:EPZM) » Definitions » Operating Margin %

Epizyme (Epizyme) Operating Margin % : -108.39% (As of Jun. 2022)


View and export this data going back to 2013. Start your Free Trial

What is Epizyme Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Epizyme's Operating Income for the three months ended in Jun. 2022 was $-29.84 Mil. Epizyme's Revenue for the three months ended in Jun. 2022 was $27.53 Mil. Therefore, Epizyme's Operating Margin % for the quarter that ended in Jun. 2022 was -108.39%.

Good Sign:

Epizyme Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Epizyme's Operating Margin % or its related term are showing as below:

EPZM' s Operating Margin % Range Over the Past 10 Years
Min: -5177.7   Med: -690.09   Max: -1.7
Current: -370.04


EPZM's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -172 vs EPZM: -370.04

Epizyme's 5-Year Average Operating Margin % Growth Rate was 9.70% per year.

Epizyme's Operating Income for the three months ended in Jun. 2022 was $-29.84 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2022 was $-196.15 Mil.


Epizyme Operating Margin % Historical Data

The historical data trend for Epizyme's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epizyme Operating Margin % Chart

Epizyme Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,368.42 -590.35 -744.29 -1,430.12 -635.88

Epizyme Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -447.65 -1,233.22 -442.77 -585.20 -108.39

Competitive Comparison of Epizyme's Operating Margin %

For the Biotechnology subindustry, Epizyme's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epizyme's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Epizyme's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Epizyme's Operating Margin % falls into.



Epizyme Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Epizyme's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-237.992 / 37.427
=-635.88 %

Epizyme's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=-29.837 / 27.528
=-108.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Epizyme  (NAS:EPZM) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Epizyme Operating Margin % Related Terms

Thank you for viewing the detailed overview of Epizyme's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Epizyme (Epizyme) Business Description

Traded in Other Exchanges
N/A
Address
400 Technology Square, 4th Floor, Cambridge, MA, USA, 02139
Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. Its product candidates include one approved product, TAZVERIK (tazemetostat), an inhibitor of the EZH2. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.
Executives
Jeffery Kutok officer: Chief Scientific Officer 784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jerald Korn officer: Chief Operating Officer 128 GORDON RD, NEWTON MA 02468
Joseph Beaulieu officer: Corporate Controller C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Shefali Agarwal officer: Chief Medical Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Royalty Pharma Investments 2019 Icav director, 10 percent owner C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022
Pablo G. Legorreta director 110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
Carol Stuckley director C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Roy A Beveridge, director 500 W MAIN ST, LOUISVILLE KY 40202
David M Mott director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Robert B Bazemore director, officer: President & CEO 33 HAYDEN AVE, LEXINGTON MA 02421
Matthew Ros officer: Chief Operating Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Tombesi officer: Chief Financial Officer 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Victoria Vakiener officer: Chief Commercial Officer C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Carl Goldfischer director 161 WEST 61ST STREET, NEW YORK NY 10022
Rp Management, Llc director 110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022